Nanoscope Therapeutics to Showcase MCO-010 Clinical and Manufacturing Data at ASGCT 2026
Event summary
- Nanoscope Therapeutics will present clinical and manufacturing data on MCO-010 at ASGCT 2026, May 11-15, 2026.
- Key presentations include bilateral vision improvement and color discrimination in RP and Stargardt disease patients.
- Company nearing completion of US BLA submission for MCO-010.
- Poster sessions will cover AAV manufacturing challenges and CMC regulatory insights.
The big picture
Nanoscope's presentations at ASGCT 2026 come as the company positions MCO-010 as a potential standard of care for retinal degenerative diseases. The mutation-agnostic therapy's one-time, in-office administration could disrupt current treatment paradigms if approved. The company's strategic focus on multiple indications (RP, Stargardt, GA) and global regulatory designations suggests ambitious commercial aspirations.
What we're watching
- Regulatory Timeline
- Whether Nanoscope can complete and secure FDA approval for MCO-010 BLA submission in 2026.
- Clinical Efficacy
- How the bilateral vision improvement and color discrimination data will impact MCO-010's market potential.
- Manufacturing Scalability
- The pace at which Nanoscope can address AAV manufacturing challenges to support commercialization.
Related topics